Best Pharma & Healthcare Funds
Defensive-growth exposure to pharma, hospitals and diagnostics.
Data updated · 19 direct-growth funds ranked by a transparent 0–100 Smart Score
| ⚖ VS | Fund | Score ↓ | Verdict | 1Y | 3Y | 5Y | Sharpe | Sortino | Std Dev | Alpha | Beta | VR★ | P/E | Expense | AUM | Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities SBI | 83 | Strong Buy | 12.7% | 21.8% | 16.9% | 1.12 | 1.66 | 14.8 | 5.7 | 0.83 | — | 56.7 | 1.01% | ₹5.9k Cr | 13.8y | |
| HDFC Pharma And Healthcare HDFC | 82 | Strong Buy | 19.9% | 28.4% | — | 1.39 | 2.20 | 16.3 | 10.9 | 0.89 | — | 48.5 | 1.03% | ₹3.5k Cr | 3.0y | |
| Kotak Healthcare Kotak | 68 | Buy | 20.5% | — | — | 0.96 | 1.35 | 14.5 | 13.3 | 0.68 | — | 50.6 | 1.04% | ₹838 Cr | 2.9y | |
| Invesco India Pharma and Healthcare Invesco | 68 | Buy | — | — | — | — | — | — | — | — | — | 64.5 | 0.59% | ₹436 Cr | 0.1y | |
| DSP Healthcare DSP | 67 | Buy | 12.6% | 19.5% | 14.8% | 0.98 | 1.42 | 15.2 | 4.6 | 0.79 | — | 35.2 | 0.75% | ₹3.8k Cr | 7.9y | |
| Mirae Asset Healthcare Mirae Asset | 64 | Buy | 13.9% | 21.3% | 14.6% | 0.96 | 1.47 | 16.4 | 3.5 | 0.94 | — | 47.5 | 0.62% | ₹3.5k Cr | 8.4y | |
| UTI Healthcare UTI | 61 | Hold | 10.2% | 21.3% | 14.3% | 1.02 | 1.54 | 16.2 | 4.8 | 0.90 | — | 40.8 | 1.34% | ₹1.4k Cr | 13.8y | |
| ICICI Pru Healthcare ICICI Pru | 57 | Hold | 2.9% | 20.4% | 14.9% | 0.94 | — | 16.4 | 3.6 | 0.90 | — | — | 1.32% | ₹6.9k Cr | 8.3y | |
| PGIM India Healthcare PGIM India | 51 | Hold | 15.2% | — | — | 0.21 | 0.28 | 13.1 | 7.4 | 0.65 | — | 51.8 | 0.96% | ₹130 Cr | 1.9y | |
| WhiteOak Capital Pharma And Heathcare WhiteOak | 50 | Hold | 14.9% | — | — | — | — | — | — | — | — | 51.0 | 1.09% | ₹927 Cr | 2.7y | |
| Bajaj Finserv Healthcare Bajaj Finserv | 47 | Hold | 14.1% | — | — | 0.04 | 0.05 | 13.5 | 3.8 | 0.68 | — | 48.1 | 0.90% | ₹405 Cr | 1.8y | |
| ABSL Pharma And Healthcare Aditya Birla Sun Life | 42 | Avoid | 10.6% | 18.9% | 12.9% | 0.92 | 1.37 | 15.6 | 2.6 | 0.90 | — | 48.5 | 1.07% | ₹1.1k Cr | 7.3y | |
| LIC MF Healthcare LIC | 32 | Avoid | 7.4% | 20.1% | 11.1% | 0.93 | 1.35 | 16.4 | 3.5 | 0.89 | — | 51.9 | 1.37% | ₹99 Cr | 7.7y | |
| Nippon India Pharma Nippon India | 32 | Avoid | 5.6% | 16.4% | 12.5% | 0.81 | 1.08 | 15.1 | 1.1 | 0.85 | — | 38.5 | 1.00% | ₹9.2k Cr | 13.8y | |
| Baroda BNP Paribas Health And Wellness Baroda BNP Paribas | 28 | Avoid | 5.8% | — | — | -0.32 | -0.44 | 11.7 | 1.5 | 0.57 | — | 44.6 | 1.51% | ₹487 Cr | 1.4y | |
| Quant Healthcare Quant | 27 | Avoid | 12.0% | 18.9% | — | 0.83 | 0.98 | 18.4 | 3.6 | 0.88 | — | 27.0 | 1.51% | ₹431 Cr | 3.3y | |
| ITI Pharma And Healthcare ITI | 27 | Avoid | 5.6% | 17.7% | — | 0.81 | 1.09 | 16.8 | 1.2 | 0.94 | — | 47.1 | 0.92% | ₹266 Cr | 4.9y | |
| Tata India Pharma & Healthcare Tata | 27 | Avoid | 2.8% | 17.4% | 13.3% | 0.79 | 1.16 | 16.8 | -0.8 | 0.99 | — | 40.3 | 1.07% | ₹1.5k Cr | 10.8y | |
| Bandhan Healthcare Bandhan | 24 | Avoid | — | — | — | — | — | — | — | — | — | 39.4 | 1.31% | ₹333 Cr | 0.9y |
Pharma & Healthcare funds — quick answers
›Which is the best Pharma & Healthcare mutual fund right now?
SBI Healthcare Opportunities currently ranks #1 of 19 Pharma & Healthcare funds with a FundLens Smart Score of 83/100 (Strong Buy). It returned 21.8% over 3 years and 16.9% over 5 years at a 1.01% expense ratio (direct plan). Rankings are recomputed from data updated 18 Oct 2026.
›Which Pharma & Healthcare fund has the best risk-adjusted returns?
HDFC Pharma And Healthcare leads the category on the Sortino ratio at 2.20 (Sharpe 1.39) — meaning it has delivered the most return per unit of downside risk among Pharma & Healthcare funds.
›Which Pharma & Healthcare fund has the lowest expense ratio?
Invesco India Pharma and Healthcare charges 0.59% a year (direct plan) — the lowest in the category. Lower fees compound in your favour over long holding periods.
›Which is the smallest Pharma & Healthcare fund by AUM?
LIC MF Healthcare manages ₹99 Cr, the smallest in the category. Smaller funds can be nimbler, but check track record and costs before treating size alone as an edge.
›How long should I stay invested in a Pharma & Healthcare fund?
Pharma & Healthcare funds carry very high risk, so a horizon of 7+ years is generally sensible. Defensive-growth exposure to pharma, hospitals and diagnostics. This is research, not investment advice.
Want these answers conversationally? Ask FundLens · New to the ratios? Sharpe vs Sortino, explained